Recent approvals in hepatocellular carcinoma (HCC) have increased the treatment options available for patients with this disease, leading to improved clinical outcomes. However, there is no single treatment strategy that can be applied to all patients with HCC. Hence, it creates an unmet educational need for establishing the best practice and standard of care for patients with HCC to provide the best chance of survival.
In this webcast, Dr. Ghassan Abou-Alfa and a panel of HCC experts elucidate best practices for the incorporation of emerging agents and treatment strategies into your clinical practice.
Earn CME for this activity: https://www.naccme.com/program/2018-a62801-2